Enhanced cis-platinum ototoxicity in children with brain tumours who have received simultaneous or prior cranial irradiation.
We report on four children who received cis-platinum simultaneously with, or in one case 10 months after, cranial irradiation and experienced exaggerated ototoxicity affecting all audible frequencies. The hearing loss was severe, affecting the critical areas for speech perception, and necessitated the provision of bilateral hearing aids. The audiograms of these patients are shown and compared to those of four children who had received cis-platinum as part of their treatment for neuroblastoma but without cranial irradiation. The precipitation of the exaggerated hearing loss with the administration of cis-platinum in one patient 10 months after finishing cranial irradiation suggests that care should be taken in the timing of cis-platinum administration in relation to concurrent or previous cranial irradiation.
Walker
D A
DA
Department of Clinical Haematology and Oncology, Royal Children's Hospital, Victoria, Australia.
Pillow
J
J
Waters
K D
KD
Keir
E
E
D000293:Adolescent; D001921:Brain / Q000528:radiation effects*; D001932:Brain Neoplasms / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D002945:Cisplatin / Q000009:adverse effects*; D003131:Combined Modality Therapy; D004423:Ear / Q000187:drug effects*; D006312:Hearing Loss, Bilateral / Q000139:chemically induced; D006801:Humans; D008297:Male; D011878:Radiotherapy / Q000009:adverse effects*
D002945:Cisplatin